Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy

Background: The indications of Immunotherapy (IO) for metastatic Non Small Cell Lung Cancer (mNSCLC) are broadening. Although different studies have proved the efficacy of IO in this setting, only a minority of patients (pts) gains advantage from IO and predictive variables of Long Term Benefit (LTB) are incompletely understood. Methods: We retrospectively collected data about all consecutive mNSCLC pts treated with IO at Istituto Nazionale dei...